Welcome to our dedicated page for Ramm Pharma news (Ticker: RAMMF), a resource for investors and traders seeking the latest updates and insights on Ramm Pharma stock.
RAMM Pharma Corp. (RAMMF) generates news that spans pharmaceutical cannabis, hemp-based products, veterinary CBD medicines and international expansion. Company releases emphasize its activities in cannabinoid pharmacology, registered plant-derived cannabinoid pharmaceuticals in Uruguay and several Latin American countries, and vertically integrated hemp and cannabis operations in Europe through subsidiaries such as Canapar Corp. and HemPoland.
Investors following RAMM-related news can expect updates on regulatory milestones, product registrations and approvals, particularly for cannabinoid pharmaceuticals and veterinary formulations like NettaVet 10% CBD Formulation. The company has highlighted approvals from Uruguayan authorities, progress at its GMP-certified formulation facility in Montevideo, and developments in European regulatory frameworks for CBD that affect its operations.
Corporate news has also covered acquisitions and integration of European businesses, including the purchase of HemPoland and the full acquisition of Canapar, as well as strategic initiatives to build a vertically integrated cannabis and hemp platform. More recent disclosures describe a proposed investment transaction with The Global South S.A.S., including details of the contemplated equity stake and call option, the need for financing, and the requirement for minority shareholder and regulatory approvals.
This news page aggregates such announcements, allowing readers to review RAMM s historical and ongoing disclosures about its pharmaceutical, veterinary, hemp and cannabis activities, its European and Latin American footprint, and its corporate transactions. Users interested in RAMM Pharma s evolving business model and regulatory environment can consult this feed for company-issued updates.
Summary not available.
Summary not available.
Summary not available.
Ramm Pharma Corp. (CSE: RAMM) announced its application for a temporary management cease trade order (MCTO) due to delays in filing its audited financial statements for the year ended October 31, 2022. The company, citing complexities from its acquisition of HemPoland S.p.a. Z.o.o., is unable to meet the February 28, 2023, deadline for the 2023 filings. Ramm Pharma expects to need approximately three additional weeks to finalize the filings. The MCTO will restrict trading by certain insiders but will not impact other shareholders. The company assures compliance with relevant regulations and maintains confidence in its financial reporting timeline.
RAMM Pharma Corp. has appointed José Roldan as interim Chief Financial Officer, effective immediately, following Guillermo Delmonte's medical leave. Roldan, a public accountant with significant cannabis industry experience and a background with KPMG Uruguay, aims to enhance the company's financial oversight. RAMM Pharma, a leader in cannabinoid pharmacology, operates in Uruguay and Europe, focusing on cannabinoid pharmaceuticals and hemp-based products. The company is also developing a range of new products across various stages of approval.
RAMM Pharma Corp. has announced the acquisition of HemPoland S.p.a. Z.o.o. from The Green Organic Dutchman for C$1.2 million. This strategic move enhances RAMM's access to HemPoland's distribution network and premium hemp brands. The acquisition follows RAMM's previous purchase of Canapar Corp. in 2021, further solidifying its foothold in the European market. RAMM, recognized for its cannabinoid pharmacology, operates internationally, with pharmaceutical products approved for sale in various Latin American countries and significant operations in Europe.
RAMM Pharma Corp. announced its intention to initiate a normal course issuer bid (NCIB) to purchase up to 5% of its currently issued and outstanding common shares. The NCIB is set to commence around August 22, 2022, and will last for 12 months. Shares will be bought on the Canadian Securities Exchange (CSE) at prevailing market prices and subsequently cancelled. This move is a response to the company's assessment that its shares are undervalued. RAMM Pharma is a leader in cannabinoid pharmacology, with operations in Uruguay and Italy.
On February 22, 2022, Ramm Pharma Corp. (CSE: RAMM) announced that it would not meet the deadline of February 28, 2022, for filing its annual audited financial statements for the year ended October 31, 2021. The Ontario Securities Commission indicated that a cease trade order (CTO) will be issued due to this delay. The Company expects to file the required documents before the end of the week to revoke the CTO. Ramm Pharma specializes in cannabinoid pharmaceuticals and operates in multiple countries, including Uruguay and Italy.
RAMM Pharma Corp. (CSE: RAMM) has applied for a temporary management cease trade order (MCTO) due to delays in filing its 2022 financial statements, which include audited financials and certifications. The company is unable to meet the February 28, 2022 deadline due to complexities from an acquisition and a change of auditors. While the company remains confident in its ability to finalize the filings, it anticipates a three-week delay, expecting to complete the necessary preparations within two months. RAMM Pharma is not subject to insolvency proceedings.
RAMM Pharma Corp. (CSE: RAMM) updates on its European operations and regulatory advancements. The company, through Canapar Corp., aims to be a leader in Europe's cannabis sector with the continent's largest extraction facility, expected to achieve EU-GMP standards in 2023, producing 5,000 kg of CBD annually. Regulatory changes in Germany and France enhance RAMM’s growth potential in the $37 billion EU cannabis market by 2027. Additionally, RAMM has streamlined operations post-Canapar acquisition, reducing costs. Interim CFO Guillermo Delmonte replaces departing Guillermo Varela.